Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies
(2010) In International Journal of Cancer 126(7). p.1702-1715- Abstract
- Several prospective studies have shown a moderate positive association between increasing circulating insulin-like growth factor-I (IGF-I) levels and colorectal cancer risk. However, the associations were often statistically nonsignificant, and the relationship of cancer risk with IGF-I's major binding protein, IGFBP-3, showed major discrepancies between studies. We investigated the association of colorectal cancer risk with serum IGF-I, total and intact IGFBP-3, in a case-control study nested within the EPIC cohort (1,121 cases of colorectal cancer and 1,121 matched controls). Conditional logistic regression was used to adjust for possible confounders. Our present study results were combined in a meta-analysis with those from 9 previous... (More)
- Several prospective studies have shown a moderate positive association between increasing circulating insulin-like growth factor-I (IGF-I) levels and colorectal cancer risk. However, the associations were often statistically nonsignificant, and the relationship of cancer risk with IGF-I's major binding protein, IGFBP-3, showed major discrepancies between studies. We investigated the association of colorectal cancer risk with serum IGF-I, total and intact IGFBP-3, in a case-control study nested within the EPIC cohort (1,121 cases of colorectal cancer and 1,121 matched controls). Conditional logistic regression was used to adjust for possible confounders. Our present study results were combined in a meta-analysis with those from 9 previous prospective studies to examine the overall evidence for a relationship of prediagnostic serum IGF-I with colorectal cancer risk. In the EPIC study, serum concentrations of IGF-I and IGFBP-3 showed no associations with risk of colorectal cancer overall. Only in subgroup analyses did our study show moderate positive associations of IGF-I levels with risk, either among younger participants only (and only for colon cancer) or among participants whose milk intakes were in the lowest tertile of the population distribution (RR for an increase of 100 ng/ml = 1.43 [95% CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive association remained between serum IGF-I and colorectal cancer risk overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in IGF-I). Overall, data from our present study and previous prospective studies combined indicate a relatively modest association of colorectal cancer risk with serum IGF-I. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1568161
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- European Prospective Investigation into Cancer (EPIC), control study, nested case, insulin-like growth factor-I (IGF-I), colorectal neoplasms, meta-analysis
- in
- International Journal of Cancer
- volume
- 126
- issue
- 7
- pages
- 1702 - 1715
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000274940200017
- scopus:77449111832
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.24927
- language
- English
- LU publication?
- yes
- id
- 6a5c74bd-dd21-43d3-a49a-df0c83753b1a (old id 1568161)
- date added to LUP
- 2016-04-01 10:32:00
- date last changed
- 2022-05-17 23:51:32
@article{6a5c74bd-dd21-43d3-a49a-df0c83753b1a,
abstract = {{Several prospective studies have shown a moderate positive association between increasing circulating insulin-like growth factor-I (IGF-I) levels and colorectal cancer risk. However, the associations were often statistically nonsignificant, and the relationship of cancer risk with IGF-I's major binding protein, IGFBP-3, showed major discrepancies between studies. We investigated the association of colorectal cancer risk with serum IGF-I, total and intact IGFBP-3, in a case-control study nested within the EPIC cohort (1,121 cases of colorectal cancer and 1,121 matched controls). Conditional logistic regression was used to adjust for possible confounders. Our present study results were combined in a meta-analysis with those from 9 previous prospective studies to examine the overall evidence for a relationship of prediagnostic serum IGF-I with colorectal cancer risk. In the EPIC study, serum concentrations of IGF-I and IGFBP-3 showed no associations with risk of colorectal cancer overall. Only in subgroup analyses did our study show moderate positive associations of IGF-I levels with risk, either among younger participants only (and only for colon cancer) or among participants whose milk intakes were in the lowest tertile of the population distribution (RR for an increase of 100 ng/ml = 1.43 [95% CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive association remained between serum IGF-I and colorectal cancer risk overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in IGF-I). Overall, data from our present study and previous prospective studies combined indicate a relatively modest association of colorectal cancer risk with serum IGF-I.}},
author = {{Rinaldi, Sabina and Cleveland, Rebecca and Norat, Teresa and Biessy, Carine and Rohrmann, Sabine and Linseisen, Jakob and Boeing, Heiner and Pischon, Tobias and Panico, Salvatore and Agnoli, Claudia and Palli, Domenico and Tumino, Rosario and Vineis, Paolo and Peeters, Petra H. M. and van Gils, Carla H. and Bueno-de-Mesquita, Bas H. and Vrieling, Alina and Allen, Naomi E. and Roddam, Andrew and Bingham, Sheila and Khaw, Kay-Tee and Manjer, Jonas and Borgquist, Signe and Dumeaux, Vanessa and Gram, Inger Torhild and Lund, Eiliv and Trichopoulou, Antonia and Makrygiannis, Georgios and Benetou, Vassiliki and Molina, Esther and Donate Suarez, Ignacio and Barricarte Gurrea, Aurelio and Gonzalez, Carlos A. and Tormo, Maria-Jose and Altzibar, Jone M. and Olsen, Anja and Tjonneland, Anne and Gronbaek, Henning and Overvad, Kim and Clavel-Chapelon, Francoise and Boutron-Ruault, Marie-Christine and Morois, Sophie and Slimani, Nadia and Boffetta, Paolo and Jenab, Mazda and Riboli, Elio and Kaaks, Rudolf}},
issn = {{0020-7136}},
keywords = {{European Prospective Investigation into Cancer (EPIC); control study; nested case; insulin-like growth factor-I (IGF-I); colorectal neoplasms; meta-analysis}},
language = {{eng}},
number = {{7}},
pages = {{1702--1715}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies}},
url = {{http://dx.doi.org/10.1002/ijc.24927}},
doi = {{10.1002/ijc.24927}},
volume = {{126}},
year = {{2010}},
}